Anavex gets FDA meeting to discuss pediatric inclusion in Rett syndrome Phase 3 trial

ANAVEX LIFE SCIENCES CORP.

FDA granted Anavex's request for a meeting to discuss adding pediatric patients to Phase 3 trial ANAVEX 2-73-RS-005 in Rett syndrome.
Disclosure made September 9, 2026; trial targets adult patients with ANAVEX 2-73 (blarcamesine).
Company prioritizing ANAVEX 2-73 development in early Alzheimer's, Rett, and Fragile X syndromes in the US.
Meeting could expand trial scope to pediatric population, a potential label-expansion step.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.